FindTrial
Sign In

The abnormalities of JAK, ABL and TF pathways in Ph-like ALL and targeted therapy

The abnormalities of JAK, ABL and TF pathways in Ph-like ALL and targeted therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009636
Enrollment
Unknown
Registered
2016-10-26
Start date
2016-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ph-like ALL

Interventions

EXPERIMENT GROUP:CHEMATHERAPY+TKI
control group:chematherapy

Sponsors

Tongji Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
12 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The first diagnosised Ph(-) ALL; 2. Aged between 12 and 70 years; 3. life time=3 months; 4. No serious dysfunction of organs; 5. Volunteered for the experiment and have signed informed consent To observe the plan and follow-up.

Exclusion criteria

Exclusion criteria: 1. The abnormal liver function before the experiment; 2. The abnormal renal function before the experiment; 3. HIV positive; 4. ECOG=2; 5. Infection of HBV or HCV.

Design outcomes

Primary

MeasureTime frame
remission rate;—

Secondary

MeasureTime frame
overall survival;progression free survival;—

Countries

China

Contacts

Public ContactFU JIANFEI

Shanghai Tongji Hospital

yanjh027@126.com+86 18621909612

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026